Healthcare of Ontario Pension Plan Trust Fund Trims Stock Holdings in Alkermes plc (NASDAQ:ALKS)
Healthcare of Ontario Pension Plan Trust Fund reduced its stake in Alkermes plc (NASDAQ:ALKS – Free Report) by 67.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 280,000 shares of the company’s stock after selling 579,200 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund owned about 0.17% of Alkermes worth $7,893,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in the stock. Fisher Asset Management LLC lifted its position in shares of Alkermes by 0.3% in the first quarter. Fisher Asset Management LLC now owns 131,877 shares of the company’s stock valued at $3,718,000 after acquiring an additional 449 shares in the last quarter. TCI Wealth Advisors Inc. increased its stake in Alkermes by 105.4% in the first quarter. TCI Wealth Advisors Inc. now owns 908 shares of the company’s stock valued at $26,000 after purchasing an additional 466 shares during the last quarter. Alliancebernstein L.P. increased its stake in Alkermes by 0.3% in the fourth quarter. Alliancebernstein L.P. now owns 195,581 shares of the company’s stock valued at $5,111,000 after purchasing an additional 500 shares during the last quarter. Franklin Resources Inc. increased its stake in Alkermes by 0.6% in the fourth quarter. Franklin Resources Inc. now owns 86,947 shares of the company’s stock valued at $2,272,000 after purchasing an additional 544 shares during the last quarter. Finally, Captrust Financial Advisors increased its stake in Alkermes by 4.3% in the fourth quarter. Captrust Financial Advisors now owns 13,402 shares of the company’s stock valued at $350,000 after purchasing an additional 555 shares during the last quarter. 95.21% of the stock is currently owned by hedge funds and other institutional investors.
Alkermes Trading Down 1.2 %
Shares of ALKS opened at $28.85 on Monday. The company has a market capitalization of $4.81 billion, a P/E ratio of 50.61 and a beta of 0.60. Alkermes plc has a one year low of $21.75 and a one year high of $33.71. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.48 and a current ratio of 2.87. The stock has a 50-day moving average price of $29.31 and a 200 day moving average price of $29.30.
Alkermes (NASDAQ:ALKS – Get Free Report) last issued its quarterly earnings results on Wednesday, July 26th. The company reported $0.38 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.10. The firm had revenue of $617.40 million during the quarter, compared to the consensus estimate of $572.57 million. Alkermes had a return on equity of 2.33% and a net margin of 7.04%. Sell-side analysts forecast that Alkermes plc will post 0.94 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts recently commented on the company. Mizuho upped their target price on Alkermes from $36.00 to $40.00 in a research note on Wednesday, June 7th. StockNews.com lowered Alkermes from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, September 6th. Piper Sandler upped their price target on Alkermes from $35.00 to $37.00 in a research note on Wednesday, June 7th. Cantor Fitzgerald restated an “overweight” rating on shares of Alkermes in a research note on Monday, July 10th. Finally, TheStreet upgraded Alkermes from a “c” rating to a “b” rating in a research note on Wednesday, July 26th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $33.33.
Get Our Latest Report on Alkermes
About Alkermes
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer.
Read More
Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes plc (NASDAQ:ALKS – Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Alkermes, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Alkermes wasn’t on the list.
While Alkermes currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Which stocks are major institutional investors including hedge funds and endowments buying in today’s market? Click the link below and we’ll send you MarketBeat’s list of thirteen stocks that institutional investors are buying up as quickly as they can.
